U.S. Markets close in 2 hrs 27 mins
  • S&P 500

    3,651.93
    -41.30 (-1.12%)
     
  • Dow 30

    29,231.13
    -359.28 (-1.21%)
     
  • Nasdaq

    10,807.76
    -60.16 (-0.55%)
     
  • Russell 2000

    1,655.21
    -24.37 (-1.45%)
     
  • Crude Oil

    76.63
    -2.11 (-2.68%)
     
  • Gold

    1,633.90
    -21.70 (-1.31%)
     
  • Silver

    18.48
    -0.43 (-2.30%)
     
  • EUR/USD

    0.9612
    -0.0076 (-0.7882%)
     
  • 10-Yr Bond

    3.8920
    +0.1950 (+5.27%)
     
  • Vix

    32.25
    +2.33 (+7.79%)
     
  • GBP/USD

    1.0680
    -0.0177 (-1.6266%)
     
  • USD/JPY

    144.7360
    +1.4160 (+0.9880%)
     
  • BTC-USD

    19,074.13
    +137.47 (+0.73%)
     
  • CMC Crypto 200

    437.54
    +4.44 (+1.03%)
     
  • FTSE 100

    7,020.95
    +2.35 (+0.03%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting

·1 min read
  • Curis Inc (NASDAQ: CRISpresented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting.

  • The TakeAim Lymphoma Phase 1/2 study is investigating emavusertib as monotherapy and in combination with ibrutinib in patients with R/R hematologic malignancies.

  • The combination appeared to be well tolerated, with no dose-limiting toxicities (DLTs) at 200mg of emavusertib.

  • Two DLTs were observed at 300mg (stomatitis and syncope).

  • 8 of 9 evaluable patients experienced a reduction in tumor burden.

  • Related: After Leukemia Trial, FDA Puts Partial Hold On Curis' Lymphoma Study.

  • The TakeAim Leukemia study is a Phase 1/2 study examining emavusertib use as monotherapy and in combination with azacitidine or venetoclax in patients with R/R AML or high-risk MDS.

  • Emavusertib was well-tolerated across multiple dose levels, and no dose-limiting myelosuppression was observed.

  • In patients with spliceosome-mutated R/R AML, CR/CRh rate of 40% (2 out of 5 patients) (CRh=complete response with partial hematologic recovery).

  • Consistent tumor burden reduction was observed. 4 out of 5 patients achieved blast reduction, three by ≥ 50%.

  • In patients with spliceosome-mutated R/R MDS, the objective response rate was 57%.

  • In patients with FLT3-mutated R/R AML, the CR rate was 33%.

  • Price Action: CRIS shares are up 14.9% at $1.08 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.